文献速递浆细胞疾病

同时靶向蛋白翻译与核蛋白输出可增强抗骨髓瘤效应

Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects.
PubMed 文献 · Blood Adv · 2023-01-01

在体外多发性骨髓瘤(MM)细胞中,评估核输出抑制剂selinexor与蛋白翻译抑制联合的抗MM效果。selinexor剂量依赖性降低eIF4E、IKZF1和c-MYC蛋白水平;敲低eIF4E增强selinexor抗增殖作用、使耐药MM细胞对selinexor敏感并增加凋亡;selinexor与蛋白翻译药理学抑制剂联用显示协同抗MM效应。

要点

  • selinexor剂量依赖性降低MM细胞eIF4E、IKZF1和c-MYC蛋白水平。
  • 敲低eIF4E增强selinexor抗增殖作用并使耐药MM细胞对selinexor敏感。
  • selinexor与蛋白翻译抑制剂联用在体外显示协同抗MM效应。

核心结论

  • 结果提示selinexor联合eIF4E抑制剂在体外具有协同抗MM效应。
  • 本研究为selinexor耐药潜在机制提供理解,并为selinexor联合eIF4E抑制剂治疗MM提供依据。

研究设计与样本

  • 体外研究,使用多发性骨髓瘤(MM)细胞评估蛋白翻译与核输出联合抑制的效果。
  • 使用多西环素诱导型pLKO-Tet-On载体敲低eIF4E。

主要发现

  • selinexor剂量依赖性降低eIF4E、IKZF1和c-MYC蛋白水平。
  • 敲低eIF4E显著增强selinexor的抗增殖作用、使耐药MM细胞对selinexor敏感并增加MM细胞凋亡。
  • 免疫荧光分析显示,与单用selinexor相比,联合处理使残余eIF4E向细胞核的定位增加。
  • eIF4E过表达至少部分逆转selinexor在MM细胞中的作用,表现为减少G1细胞周期阻滞并使selinexor-IC50增加10倍。
  • selinexor与蛋白翻译药理学抑制剂联用显示协同抗MM效应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selinexor (KPT-330) is a small molecule inhibitor of XPO1, which mediates the transport of tumor suppressor proteins, oncogene messenger RNAs, and other proteins involved in governing cell growthfrom the cell nucleus to the cytoplasm. It is overexpressed in many cancer types. Because eukaryotic translation initiator factor 4E (eIF4E) plays a critical role in protein translation in cancer cells in multiple myeloma (MM), we evaluated the effectiveness of combined inhibition of protein translation and nuclear export in MM. Selinexor, an inhibitor of nuclear protein export, dose-dependently decreased eIF4E, IKZF1, and c-MYC protein levels. Using a doxycycline-inducible-pLKO-Tet-On vector, knockdown of eIF4E significantly enhanced the antiproliferative effects of selinexor, sensitized resistant MM cells to selinexor, and increased apoptosis in MM cells. Immunofluorescent analysis of MM cells showed that the combined treatment increased the localization of residual eIF4E to the nucleus compared with selinexor-only treatment. The overexpression of eIF4E at least partially rescued the effects of selinexor in MM cells by reducing G1 cell cycle arrest and increasing the selinexor-IC50 10-fold. Moreover, the combination of selinexor with pharmacologic inhibitors of protein translation showed synergistic anti-MM effects. These results suggest a synergistic anti-MM effect of selinexor combined with eIF4E inhibitors in vitro. Our work provides a better understanding of the potential mechanism of resistance to selinexor and a rationale for combining selinexor with eIF4E inhibitors for the treatment of MM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Li S, Fu J, Walker CJ, et al. Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects. Blood Adv. 2023. PMID: 36827679. doi:10.1182/bloodadvances.2021006638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。